Specifically, circP4HB enhances EMT and metastatic disease through miR-133a-5p sequestration, leading to upregulation of vimentin, advocating targeting the circP4HB/miR-133a-5p/vimentin axis as a potential therapeutic option [32], circPTPRA upregulates tumor suppressor RASSF8 by sponging miR-96-5p, and further inhibits EMT and metastasis of NSCLC cell line [33]. The gene discussed is VIM; the disease is non-small cell lung carcinoma.